Effect of Ulipristal Acetate for Uterine Fibroids

被引:0
|
作者
Deshpande, Preeti Suhas [1 ,2 ]
Deshpande, Suhas Suresh [1 ,2 ]
机构
[1] Ekopa Hosp, Dept Obstet & Gynaecol, Karad, Maharashtra, India
[2] Karad Fertil Res Ctr, Karad, Maharashtra, India
关键词
Fibroid; Ulipristal Acetate; Menorrhagia; Selective Progesterone Receptor Modulator; SPRM; MANAGEMENT; PLACEBO; SAFETY;
D O I
10.14260/jemds/2019/795
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Fibroids are the most common tumours of the female reproductive tract and have been reported to affect 20-40% of women during their reproductive years. Most fibroids are asymptomatic and require no treatment. We wanted to investigate the effectiveness of Ulipristal Acetate in reducing the fibroid volume, and giving symptomatic relief after 3 months treatment. METHODS This is a prospective interventional study conducted among 38 premenopausal women with symptomatic fibroids. They were evaluated clinically for the symptoms reported. Each underwent ultrasound before starting the treatment and after three months of Ulipristal treatment. Some patients had more than one fibroid and so in total the sizes of 56 fibroids were recorded. RESULTS After 3 months of ulipristal acetate treatment, patients had a significant improvement of all symptoms with fibroid volume reduction. CONCLUSIONS Fibroid treatment with ulipristal acetate resulted in a significant improvement of fibroid related symptoms and significant reduction in fibroid volume.
引用
收藏
页码:3675 / 3678
页数:4
相关论文
共 50 条
  • [21] Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids
    Ferrero, Simone
    Vellone, Valerio Gaetano
    Barra, Fabio
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (01) : 107 - 116
  • [22] Long-term treatment of uterine fibroids with ulipristal acetate
    Donnez, Jacques
    Vazquez, Francisco
    Tomaszewski, Janusz
    Nouri, Kazem
    Bouchard, Philippe
    Fauser, Bart C. J. M.
    Barlow, David H.
    Palacios, Santiago
    Donnez, Olivier
    Bestel, Elke
    Osterloh, Ian
    Loumaye, Ernest
    FERTILITY AND STERILITY, 2014, 101 (06) : 1565 - U405
  • [23] Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids
    Talaulikar, Vikram Sinai
    Manyonda, Isaac
    WOMENS HEALTH, 2014, 10 (06) : 565 - 570
  • [24] Treatment of Symptomatic Uterine Fibroids with Ulipristal Acetate: Endometrial Safety
    Catherino, William
    Eisenhut, Carol
    Blakesley, Rick
    Chan, Anna
    Sniukiene, Vilma
    Goldstein, Steven
    LABORATORY INVESTIGATION, 2017, 97 : 279A - 279A
  • [25] Ulipristal AcetateIn Uterine Fibroids
    Jamie D. Croxtall
    Drugs, 2012, 72 : 1075 - 1085
  • [26] Ulipristal Acetate: a Novel Option for the Medical Management of Symptomatic Uterine Fibroids
    Talaulikar, Vikram S.
    Manyonda, Isaac T.
    ADVANCES IN THERAPY, 2012, 29 (08) : 655 - 663
  • [27] Economic impact of ulipristal acetate on surgical procedures for uterine fibroids in France
    Fernandez, Herve
    Jourdain, Olivier
    Villefranque, Vincent
    Lehmann, Matthieu
    Lafuma, Antoine
    Trancart, Matthieu
    BMJ OPEN, 2017, 7 (09):
  • [28] Hepatic Safety Considerations in the Use of Ulipristal Acetate for Symptomatic Uterine Fibroids
    Semmler, Annika
    de Lange, Maria E.
    Drenth, Joost P. H.
    Vermeer, Niels S.
    Bet, Pierre M.
    Huirne, Judith A. F.
    Hehenkamp, Wouter J. K.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2025, 21 : 367 - 382
  • [29] Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues
    Perez-Lopez, F. R.
    CLIMACTERIC, 2015, 18 (02) : 177 - 181
  • [30] Pregnancy Outcomes Following Ulipristal Acetate for Uterine Fibroids: A Systematic Review
    De Gasperis-Brigante, Cassandra
    Singh, Sukhbir S.
    Vilos, George
    Kives, Sari
    Murji, Ally
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2018, 40 (08) : 1066 - +